|Articles|March 1, 2001
- Pharmaceutical Executive-03-01-2001
- Volume 0
- Issue 0
Earnings: Tough Times Ahead
Author(s)Kevin Gopal
Sodertalje, Sweden-After two consecutive years of robust postmerger growth, AstraZeneca is facing a tough 2001. The company recorded a 16 percent increase in pretax profits for 2000, but CEO Tom McKillop advises that this year}s growth will be in the 5}6 percent range when Losec/Prilosec (omeprazole)-the world}s best-selling medicine-goes off patent and the US launch of its successor Nexium (esomeprazole) is delayed.
Advertisement
Articles in this issue
almost 25 years ago
Research: New Horizonsalmost 25 years ago
Outbreak: Anthrax Alarmalmost 25 years ago
Patents: China on the Genome Mapalmost 25 years ago
Privacy, Pediatrics, and Policyalmost 25 years ago
Lilly's International Familyalmost 25 years ago
Update: Punishment and Reprievealmost 25 years ago
Shortage: Vaccine Worriesalmost 25 years ago
Gateway to Japanalmost 25 years ago
SurroundedNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
2
Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma
3
FDA Announces Agency-Wide Deployment of Agentic AI Tools
4
Report: FDA to Change Vaccine Approval Process Based on Agency’s Claim of Covid Vaccine-Related Deaths
5
